



Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents

Downloaded from <http://aidsinfo.nih.gov/guidelines> on 3/17/2013

Visit the *AIDSinfo* website to access the most up-to-date guideline.

Register for e-mail notification of guideline updates at <http://aidsinfo.nih.gov/e-news>.

Appendix A: Key to Acronyms (Last updated February 12, 2012; last reviewed February 12, 2012)

Drug Name Abbreviations

Abbreviation	Full Name
3TC	lamivudine
ABC	abacavir
APV	amprenavir
ATV	atazanavir
ATV/r	ritonavir-boosted atazanavir
AZT	zidovudine
COBI	cobicistat
d4T	stavudine
ddI	didanosine
DLV	delavirdine
DRV	darunavir
DRV/r	ritonavir- boosted darunavir
EFV	efavirenz
ETR	etravirine
EVG	elvitegravir
FPV	fosamprenavir
FPV/r	ritonavir-boosted fosamprenavir
FTC	emtricitabine
GAZT	azidothymidine glucuronide
IDV	indinavir
LPV	lopinavir
LPV/r	ritonavir-boosted lopinavir
MVC	maraviroc
NFV	nelfinavir
NVP	nevirapine
RAL	raltegravir

RPV	rilpivirine
RTV	ritonavir
SQV	saquinavir
SQV/r	ritonavir-boosted saquinavir
T20	enfuvirtide
TDF	tenofovir disoproxil fumarate
TPV	tipranavir
TPV/r	ritonavir-boosted tipranavir
ZDV	zidovudine

General Terms

Abbreviation	Full Name
ACTG	AIDS Clinical Trials Group
AIDS	acquired immune deficiency syndrome
ALT	alanine aminotransferase
ART	antiretroviral therapy
ART-CC	ART Cohort Collaboration
ARV	antiretroviral
AST	aspartate aminotransferase
AUC	area under the curve
AV	atrioventricular
bDNA	branched DNA
BID	twice daily
BMD	bone mineral density
BMI	body mass index
BUN	blood urea nitrogen
cap	capsule
CAPD	chronic ambulatory peritoneal dialysis
CBC	complete blood count
CCB	calcium channel blocker
CDC	Centers for Disease Control and Prevention
CI	confidence interval
CKD	chronic kidney disease
C _{max}	maximum plasma concentration
CME	continuing medical education

C _{min}	minimum plasma concentration
CMV	cytomegalovirus
CNICS	Centers for AIDS Research Network of Integrated Clinical Systems
CNS	central nervous system
COC	combined oral contraceptives
CPK	creatine phosphokinase
CrCl	creatinine clearance
CSF	cerebrospinal fluid
CVD	cardiovascular disease
CYP	cytochrome P
D/M	dual or mixed (tropic)
D:A:D	Data Collection on Adverse Events of Anti-HIV Drugs Study
DILI	drug-induced liver injury
DM	diabetes mellitus
DMPA	depot medroxyprogesterone acetate
DOT	directly observed therapy
DR	delayed release
DXA	dual-energy x-ray absorptiometry
EBV	Epstein-Barr virus
EC	enteric coated
ECG	electrocardiogram
EI	entry inhibitor
EIA	enzyme immunoassay
FDA	Food and Drug Administration
FI	fusion inhibitor
GHB	gamma-hydroxybutyrate
GI	gastrointestinal
HAD	HIV-associated dementia
HAV	hepatitis A virus
HBeAg	hepatitis B e antigen
HBsAg	hepatitis B surface antigen
HBV	hepatitis B virus
HCV	hepatitis C virus
HD	hemodialysis
HDL	high-density lipoprotein

HELLP	hemolysis, elevated liver enzymes, low platelet count (syndrome)
HHS	Department of Health and Human Services
HHV	human herpes virus
HHV-8	human herpes virus-8
HIV	human immunodeficiency virus
HIV-1	human immunodeficiency virus type 1
HIV-2	human immunodeficiency virus type 2
HIVAN	HIV-associated nephropathy
HLA	human leukocyte antigen
HPV	human papilloma virus
HR	hazard ratio
HRSA	Health Resource Services Administration
hsCRP	high-sensitivity C-reactive protein
HSR	hypersensitivity reaction
HTLV	human T-cell leukemia virus
HTLV-1	human T-cell leukemia virus type 1
HTLV-2	human T-cell leukemia virus type 2
IAS-USA	International Antiviral Society-USA
IC	inhibitory concentration
IDU	injection drug user
IFN- γ	interferon-gamma
IGRA	interferon-gamma release assay
IL-2	interleukin-2
IL-6	interleukin-6
IL-7	interleukin-7
IND	investigational new drug
INH	isoniazid
inj	injection
INR	international normalized ratio
INSTI	integrase strand transfer inhibitor
IQ	inhibitory quotient
IRB	Institutional Review Board
IRIS	immune reconstitution inflammatory syndrome
IUD	intrauterine device
IV	Intravenous
LDL	low-density lipoprotein
LTBI	latent tuberculosis infection

MAC	<i>Mycobacterium avium</i> complex
MDMA	methylenedioxyamphetamine
mDOT	modified directly observed therapy
MDR	multidrug-resistant
MDRD	modification of diet in renal disease (equation)
MHC	major histocompatibility complex
MI	myocardial infarction
msec	milliseconds
MSM	men who have sex with men
MTB	<i>Mycobacterium tuberculosis</i>
MTCT	mother-to-child transmission
NA-ACCORD	The North American AIDS Cohort Collaboration on Research and Design
NIH	National Institutes of Health
NNRTI	non-nucleoside reverse transcriptase inhibitor
NRTI	nucleoside reverse transcriptase inhibitor
OAR	Office of AIDS Research
OARAC	Office of AIDS Research Advisory Council
OI	opportunistic infection
PAH	pulmonary arterial hypertension
PCP	<i>Pneumocystis jiroveci</i> pneumonia
PDE5	phosphodiesterase type 5
PegIFN	peginterferon
p-gp	p-glycoprotein
PI	protease inhibitor
PK	pharmacokinetic
PMTCT	prevention of mother-to-child transmission
PNS	peripheral nervous system
PO	orally
PPI	proton pump inhibitor
PR	protease (gene)
PrEP	pre-exposure HIV prophylaxis
PT	prothrombin time
QTc	QT corrected for heart rate
RT	reverse transcriptase (gene)

RT-PCR	reverse transcriptase-polymerase chain reaction
SJS	Stevens-Johnson syndrome
soln	solution
SPT	skin patch test
STD	sexually transmitted disease
SVR	sustained virologic response
SWP	suggested wholesale price
$t_{1/2}$	half-life
tab	tablet
TAM	thymidine analogue mutation
TB	tuberculosis
TCA	tricyclic antidepressant
TDM	therapeutic drug monitoring
TEN	toxic epidermal necrosis
TG	triglyceride
the Panel	Panel on Antiretroviral Guidelines for Adults and Adolescents
TID	three times daily
TST	tuberculin skin test
UDP	uridine diphosphate
UGT	uridine diphosphate glucosyltransferase
UGT1A1	uridine diphosphate glucuronosyltransferase 1A1
ULN	upper limit of normal
VPA	valproic acid
WBC	white blood cell
WHO	World Health Organization
WITS	Women and Infants Transmission Study
XDR	extensively drug-resistant
XR	extended release